[go: up one dir, main page]

ECSP11011310A - Análogos carba - nucleósido para tratamiento antiviral - Google Patents

Análogos carba - nucleósido para tratamiento antiviral

Info

Publication number
ECSP11011310A
ECSP11011310A ECSP11011310A ECSP11011310A EC SP11011310 A ECSP11011310 A EC SP11011310A EC SP11011310 A ECSP11011310 A EC SP11011310A EC SP11011310 A ECSP11011310 A EC SP11011310A
Authority
EC
Ecuador
Prior art keywords
nucleoside
antiviral treatment
carba analogs
carba
analogs
Prior art date
Application number
Other languages
English (en)
Inventor
Paul Hrvatin
Randall L Halcomb
Manoj C Desai
Hon Chung Hui
Fadden Ryan Mc
Paul A Roethle
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41621203&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11011310(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of ECSP11011310A publication Critical patent/ECSP11011310A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/10—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with an aromatic or hetero-aromatic ring directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/12—Heterocyclic compounds containing pteridine ring systems containing pteridine ring systems condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Devices For Checking Fares Or Tickets At Control Points (AREA)
  • Digital Transmission Methods That Use Modulated Carrier Waves (AREA)

Abstract

La invención generalmente se refiere a los compuestos, composiciones y métodos de preparación con actividad antiviral, usados para el tratamiento de las infecciones del virus Flaviviridae.
ECSP11011310 2008-12-09 2011-09-08 Análogos carba - nucleósido para tratamiento antiviral ECSP11011310A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12106108P 2008-12-09 2008-12-09
US17040409P 2009-04-17 2009-04-17
US22438609P 2009-07-09 2009-07-09
US22737809P 2009-07-21 2009-07-21
US24263509P 2009-09-15 2009-09-15

Publications (1)

Publication Number Publication Date
ECSP11011310A true ECSP11011310A (es) 2011-10-31

Family

ID=41621203

Family Applications (2)

Application Number Title Priority Date Filing Date
ECSP11011189 ECSP11011189A (es) 2008-12-09 2011-07-07 Moduladores de los receptores tipo toll
ECSP11011310 ECSP11011310A (es) 2008-12-09 2011-09-08 Análogos carba - nucleósido para tratamiento antiviral

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ECSP11011189 ECSP11011189A (es) 2008-12-09 2011-07-07 Moduladores de los receptores tipo toll

Country Status (32)

Country Link
US (8) US8367670B2 (es)
EP (3) EP2818469B1 (es)
JP (3) JP5600116B2 (es)
KR (2) KR101787309B1 (es)
CN (2) CN102272134B (es)
AP (1) AP2011005745A0 (es)
AR (1) AR074506A1 (es)
AU (1) AU2009333559B2 (es)
BR (1) BRPI0923305B1 (es)
CA (1) CA2745295C (es)
CL (1) CL2011001392A1 (es)
CO (1) CO6362010A2 (es)
CY (1) CY1115176T1 (es)
DK (1) DK2364314T3 (es)
EA (3) EA021377B9 (es)
EC (2) ECSP11011189A (es)
ES (2) ES2623794T3 (es)
HR (1) HRP20140539T1 (es)
IL (2) IL213101A (es)
MX (1) MX2011006152A (es)
NZ (2) NZ593110A (es)
PE (1) PE20120106A1 (es)
PL (1) PL2364314T3 (es)
PT (2) PT2818469T (es)
RS (1) RS53347B (es)
SG (1) SG172060A1 (es)
SI (1) SI2364314T1 (es)
SM (1) SMT201400083B (es)
TW (5) TWI432436B (es)
UY (1) UY32306A (es)
WO (1) WO2010077613A1 (es)
ZA (1) ZA201104998B (es)

Families Citing this family (274)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2745295C (en) 2008-12-09 2017-01-10 Gilead Sciences, Inc. Modulators of toll-like receptors
JP5988492B2 (ja) 2009-09-02 2016-09-07 ノバルティス アーゲー Ｔｌｒ活性モジュレーターを含む免疫原性組成物
PT2477987T (pt) * 2009-09-14 2018-03-13 Gilead Sciences Inc Moduladores de recetores do tipo toll
CA2783258A1 (en) * 2009-12-23 2011-06-30 Elan Pharmaceuticals, Inc. Pteridinones as inhibitors of polo-like kinase
EA031737B1 (ru) 2010-06-03 2019-02-28 Фармасайкликс, Инк. Применение ингибиторов тирозинкиназы брутона (btk) для лечения лейкоза и лимфомы
CN105999275A (zh) 2010-09-01 2016-10-12 诺华有限公司 免疫增强剂吸附不溶性金属离子
AU2011349844B2 (en) 2010-12-20 2017-06-01 Gilead Sciences, Inc. Combinations for treating HCV
DK2663550T3 (en) * 2011-01-12 2017-03-27 Ventirx Pharmaceuticals Inc SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS
CA2828844C (en) 2011-03-02 2020-07-14 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
WO2012139028A2 (en) * 2011-04-06 2012-10-11 The Trustees Of Princeton University Anti-viral combination therapy
FR2975600B1 (fr) * 2011-05-24 2013-07-05 Assist Publ Hopitaux De Paris Agents pour le traitement de tumeurs
ES2553449T3 (es) 2011-07-06 2015-12-09 Gilead Sciences, Inc. Compuestos para el tratamiento de VIH
MX2014002363A (es) 2011-09-01 2014-04-14 Novartis Ag Formulaciones de antigenos de staphylococcus aureus con adyuvante.
AP2014007575A0 (en) 2011-09-16 2012-04-30 Gilead Pharmasset Llc Methods for treating HCV
AU2012358994A1 (en) 2011-12-20 2014-08-07 Gilead Sciences, Inc. Pharmaceutical compositions and methods for treating gastrointestinal infections and disorders
CN104519910B (zh) 2012-03-07 2017-05-03 诺华股份有限公司 肺炎链球菌抗原的含佐剂制剂
EP2822589A1 (en) 2012-03-07 2015-01-14 Novartis AG Adjuvanted formulations of rabies virus immunogens
AU2013229432A1 (en) 2012-03-08 2014-10-16 Novartis Ag Adjuvanted formulations of booster vaccines
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
EP3550031A1 (en) 2012-07-24 2019-10-09 Pharmacyclics, LLC Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
CN104602705A (zh) 2012-09-06 2015-05-06 诺华股份有限公司 血清组b脑膜炎球菌和d/t/p的联合疫苗
CN102952084A (zh) * 2012-11-15 2013-03-06 大连九信生物化工科技有限公司 一种4，6－二氯－2－甲硫基－5－硝基嘧啶的合成方法
SG11201506021XA (en) 2013-01-31 2015-08-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
ES2670863T3 (es) 2013-02-01 2018-06-01 Glaxosmithkline Biologicals Sa Administración intradérmica de composiciones inmunológicas que comprenden agonistas del receptor de tipo Toll
PE20160661A1 (es) 2013-09-12 2016-08-05 Alios Biopharma Inc Compuesto de azapiridona y sus usos de los mismos
US10548985B2 (en) 2014-01-10 2020-02-04 Birdie Biopharmaceuticals, Inc. Compounds and compositions for treating EGFR expressing tumors
CN105440135A (zh) 2014-09-01 2016-03-30 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CA2954446A1 (en) 2014-07-09 2016-01-14 Shanghai Birdie Biotech, Inc. Anti-pd-l1 combinations for treating tumors
CN112546231A (zh) 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
MA40238A (fr) * 2014-07-11 2017-05-17 Gilead Sciences Inc Modulateurs de récepteurs de type toll pour le traitement du vih
AU2015303558B2 (en) 2014-08-15 2018-07-12 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pyrrolopyrimidine compounds used as TLR7 agonist
US9573952B2 (en) * 2014-09-16 2017-02-21 Gilead Sciences, Inc. Methods of preparing toll-like receptor modulators
BR102015023450A2 (pt) 2014-09-16 2016-04-12 Gilead Sciences Inc formas sólidas de um modulador do receptor semelhante a toll
BR112017009648A2 (pt) * 2014-11-13 2017-12-19 Glaxosmithkline Biologicals Sa composto, métodos para tratamento de doenças alérgicas ou outras condições inflamatórias ou prevenção de doença, de rinite alérgica ou asma, composição, e, uso de um composto.
EA032430B1 (ru) 2014-12-24 2019-05-31 Джилид Сайэнс, Инк. Конденсированные пиримидины для лечения вич
BR112017013440A2 (pt) 2014-12-24 2018-01-09 Gilead Sciences, Inc. compostos de isoquinolina para o tratamento de hiv
TW202237569A (zh) 2014-12-24 2022-10-01 美商基利科學股份有限公司 喹唑啉化合物
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
SI3321265T1 (sl) 2015-03-04 2020-07-31 Gilead Sciences, Inc. Spojine 4,6-diamino-pirido(3,2-d)pirimidina in njihova uporaba kot modulatorji toličnih receptorjev
US10208045B2 (en) 2015-03-11 2019-02-19 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
JP2018515603A (ja) 2015-05-04 2018-06-14 ビオノル・イムノ・アクシェセルスカプＢｉｏｎｏｒ Ｉｍｍｕｎｏ ＡＳ Ｈｉｖワクチン用の投薬レジメン
NZ775222A (en) 2015-05-08 2024-09-27 Hoffmann La Roche Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
AU2016312508A1 (en) 2015-08-26 2018-02-15 Gilead Sciences, Inc. Deuterated toll-like receptor modulators
MX375353B (es) 2015-11-05 2025-03-06 Chia Tai Tianqing Pharmaceutical Group Co Ltd Compuesto de 7-(tiazol-5-il)pirrolopirimidina como agonista de tlr7
JP6864296B2 (ja) 2015-12-14 2021-04-28 エックス４ ファーマシューティカルズ， インコーポレイテッド がんを処置する方法
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
AU2016370591C1 (en) 2015-12-15 2020-09-03 Gilead Sciences, Inc. Human immunodeficiency virus neutralizing antibodies
MX2018007421A (es) 2015-12-17 2018-08-15 Gilead Sciences Inc Compuestos inhibidores de quinasa de union a tank.
PL3393468T3 (pl) 2015-12-22 2023-01-23 X4 Pharmaceuticals, Inc. Metody leczenia niedoboru odporności
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN107043380A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN107043378A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体
CN107043379A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的晶型a、其制备方法和医药用途
CN107043377A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途
CA3019394A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
HUE057924T2 (hu) * 2016-05-06 2022-06-28 Shanghai De Novo Pharmatech Co Ltd Benzazepin származék, elõállítási eljárása, gyógyászati készítmény és alkalmazása
BR102017010009A2 (pt) 2016-05-27 2017-12-12 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
EA201892375A1 (ru) 2016-05-27 2019-08-30 Джилид Сайэнс, Инк. Способы лечения инфекций, вызываемых вирусом гепатита b
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
JP7084624B2 (ja) 2016-06-21 2022-06-15 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
JP6994767B2 (ja) 2016-06-21 2022-01-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
CN108290893B (zh) * 2016-06-22 2021-01-05 四川科伦博泰生物医药股份有限公司 二氢蝶啶酮类衍生物、其制备方法及其用途
CN105943529B (zh) * 2016-06-29 2018-12-18 广州中医药大学 菊苣酸在制备防治登革热ⅱ型病毒感染的药物中的应用
AU2017286890B2 (en) * 2016-06-29 2021-09-09 Novira Therapeutics, Inc. Oxadiazepinone derivatives and their use in the treatment of hepatitis B infections
JP6935433B2 (ja) * 2016-06-29 2021-09-15 ノヴィラ・セラピューティクス・インコーポレイテッド ジアゼピノン誘導体及びｂ型肝炎感染症の治療におけるその使用
EP3597646B1 (en) 2016-08-19 2023-06-21 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
CN109689627B (zh) * 2016-08-26 2022-10-11 高雄医学大学 吡唑基喹啉化合物及其制备方法与医药组成物
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
IL284255B (en) * 2016-08-29 2022-07-01 Hoffmann La Roche 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
ES2826748T3 (es) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
JP6746776B2 (ja) 2016-09-02 2020-08-26 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体調節剤化合物
TWI720250B (zh) 2016-09-13 2021-03-01 瑞士商赫孚孟拉羅股份公司 利用tlr7促效劑及hbv蛋白殼組裝抑制劑之組合治療
WO2018064080A1 (en) 2016-09-28 2018-04-05 Gilead Sciences, Inc. Benzothiazol-6-yl acetic acid derivatives and their use for treating hiv infection
IL308894A (en) 2016-10-14 2024-01-01 Prec Biosciences Inc Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
WO2018081292A1 (en) 2016-10-27 2018-05-03 Gilead Sciences, Inc. Crystalline forms of darunavir free base, hydrate, solvates and salts
PT3546457T (pt) * 2016-11-28 2021-08-06 Jiangsu Hengrui Medicine Co Derivado de pirazolo-heteroarílico, método de preparação e a utilização médica do mesmo
CA3046790A1 (en) * 2016-12-13 2018-06-21 Bolt Biotherapeutics, Inc. Antibody adjuvant conjugates
EP3554344A1 (en) * 2016-12-14 2019-10-23 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tlr modulator
WO2018137614A1 (zh) * 2017-01-24 2018-08-02 江苏恒瑞医药股份有限公司 杂芳基并噻二嗪-2,2-二氧化物类衍生物、其制备方法及其在医药上的应用
TW202510891A (zh) 2017-01-31 2025-03-16 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
JOP20180008A1 (ar) 2017-02-02 2019-01-30 Gilead Sciences Inc مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
FI3603619T3 (fi) 2017-03-29 2025-09-25 Sumitomo Pharma Co Ltd Rokoteadjuvanttiformulaatio
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
JP2020520379A (ja) 2017-05-18 2020-07-09 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． ヘテロアリール−ピラゾール誘導体ならびにその調製方法および医学的適用
CN108948016B (zh) * 2017-05-19 2021-02-26 江苏恒瑞医药股份有限公司 嘌呤酮类衍生物、其制备方法及其在医药上的应用
CN110996952A (zh) * 2017-06-21 2020-04-10 X4 制药有限公司 用于治疗癌症的方法
KR102324568B1 (ko) 2017-06-21 2021-11-10 길리애드 사이언시즈, 인코포레이티드 HIV gp120 및 CD3을 표적화하는 다중특이적 항체
CN110769827A (zh) 2017-06-23 2020-02-07 博笛生物科技有限公司 药物组合物
US12090163B2 (en) * 2017-06-30 2024-09-17 Cipla Limited Pharmaceutical compositions
ES2969496T3 (es) 2017-08-01 2024-05-20 Gilead Sciences Inc Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2- il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
AR112413A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas sólidas de un inhibidor de la cápside del vih
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
EP3672970A1 (en) 2017-08-22 2020-07-01 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
WO2019057158A1 (zh) * 2017-09-22 2019-03-28 江苏恒瑞医药股份有限公司 稠合杂芳基衍生物、其制备方法及其在医药上的应用
TWI714942B (zh) * 2017-10-05 2021-01-01 高雄醫學大學 用於預防或治療罹患登革熱所引起之發炎反應的醫藥組合物及其用途
JOP20180092A1 (ar) 2017-10-13 2019-04-13 Gilead Sciences Inc مثبطات hiv بروتياز
WO2019084020A1 (en) 2017-10-24 2019-05-02 Gilead Sciences, Inc. METHODS OF TREATING PATIENTS CO-INFECTED BY A VIRUS AND TUBERCULOSIS
WO2019084060A1 (en) 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
CN109824670B (zh) * 2017-11-23 2021-11-05 四川科伦博泰生物医药股份有限公司 喋啶酮类化合物或其盐的多晶型物及其制备方法和用途
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
JP2021506827A (ja) 2017-12-15 2021-02-22 シルバーバック セラピューティックス インコーポレイテッド 肝炎の治療用の抗体コンストラクト−薬物コンジュゲート
PT3728252T (pt) 2017-12-18 2023-10-26 Bristol Myers Squibb Co Compostos 4-azaindol
WO2019123340A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2019123339A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
RU2020124007A (ru) 2017-12-21 2022-01-21 Сумитомо Дайниппон Фарма Ко., Лтд. Комбинированный препарат, включающий агонист tlr7
CN111699187A (zh) 2018-02-12 2020-09-22 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的新的砜化合物和衍生物
MY196582A (en) 2018-02-13 2023-04-19 Gilead Sciences Inc PD-1/PD-L1 Inhibitors
WO2019161017A1 (en) 2018-02-15 2019-08-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
US10696657B2 (en) 2018-02-16 2020-06-30 Gilead Sciences, Inc. Methods and intermediates for preparing therapeutic compounds
KR102526964B1 (ko) 2018-02-26 2023-04-28 길리애드 사이언시즈, 인코포레이티드 Hbv 복제 억제제로서의 치환된 피롤리진 화합물
JP7089596B2 (ja) 2018-02-28 2022-06-22 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 肝がんの治療及び予防のための７位置換スルホンイミドイルプリノン化合物及び誘導体
EP3774883A1 (en) 2018-04-05 2021-02-17 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
WO2019204609A1 (en) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US11485741B2 (en) 2018-04-24 2022-11-01 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (TLR7) agonists
TW202014193A (zh) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 包含碳環核苷酸之2’3’－環二核苷酸
CN110526917B (zh) * 2018-05-25 2021-09-03 江苏恒瑞医药股份有限公司 一种吡唑并杂芳基类衍生物的可药用盐、晶型及其制备方法
MX2020012651A (es) * 2018-05-25 2021-02-02 Jiangsu Hengrui Medicine Co Forma de cristal de clorhidrato de derivado de pirazoloheteroarilo, y metodo de preparacion.
CN110526918B (zh) * 2018-05-25 2021-09-03 江苏恒瑞医药股份有限公司 一种吡唑并杂芳基类衍生物的晶型及制备方法
SG11202012043RA (en) 2018-07-03 2021-01-28 Gilead Sciences Inc Antibodies that target hiv gp120 and methods of use
CN112384505B (zh) 2018-07-06 2025-05-27 吉利德科学公司 治疗性的杂环化合物
US11186579B2 (en) 2018-07-06 2021-11-30 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
PT3820572T (pt) 2018-07-13 2023-11-10 Gilead Sciences Inc Inibidores pd-1/pd-l1
TWI842721B (zh) 2018-07-16 2024-05-21 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
IL280332B2 (en) 2018-07-23 2025-05-01 Japan As Represented By Director General Of Nat Institute Of Infectious Diseases A preparation containing influenza vaccine
TWI829205B (zh) 2018-07-30 2024-01-11 美商基利科學股份有限公司 抗hiv化合物
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US20200113912A1 (en) 2018-09-12 2020-04-16 Silverback Therapeutics, Inc. Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates
EP3860717A1 (en) 2018-10-03 2021-08-11 Gilead Sciences, Inc. Imidozopyrimidine derivatives
CN111072667A (zh) * 2018-10-22 2020-04-28 罗欣药业(上海)有限公司 五元或六元杂环并嘧啶类化合物及其用途
EP3870566A1 (en) 2018-10-24 2021-09-01 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US11071730B2 (en) 2018-10-31 2021-07-27 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
PL3873903T3 (pl) 2018-10-31 2024-05-20 Gilead Sciences, Inc. Podstawione związki 6-azabenzimidazolu jako inhibitory hpk1
CN111349152B (zh) * 2018-12-20 2022-04-05 深圳翰宇药业股份有限公司 一种制备胸腺法新的方法
MX2021009496A (es) 2019-02-08 2021-09-08 Progeneer Inc Complejo de colesterol-agonista del receptor 7 u 8 tipo larga distancia, y uso del mismo.
WO2020176505A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
WO2020176510A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
CN113543851B (zh) 2019-03-07 2025-03-18 捷克共和国有机化学与生物化学研究所 2’3’-环二核苷酸及其前药
US20220143061A1 (en) 2019-03-07 2022-05-12 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020197991A1 (en) 2019-03-22 2020-10-01 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
US20200347036A1 (en) 2019-04-17 2020-11-05 Gilead Sciences, Inc. Solid forms of an hiv protease inhibitor
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202104210A (zh) 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑
TWI762925B (zh) 2019-05-21 2022-05-01 美商基利科學股份有限公司 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
TW202408568A (zh) 2019-05-22 2024-03-01 美商基利科學股份有限公司 Tlr7調節化合物及hiv疫苗之組合
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2020255038A1 (en) * 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
WO2020257407A1 (en) 2019-06-19 2020-12-24 Silverback Therapeutics, Inc. Anti-mesothelin antibodies and immunoconjugates thereof
US20210009718A1 (en) 2019-06-25 2021-01-14 Gilead Sciences, Inc. FLT3L-Fc FUSION PROTEINS AND METHODS OF USE
TWI879779B (zh) 2019-06-28 2025-04-11 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
KR20220047277A (ko) 2019-07-16 2022-04-15 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
US20220257619A1 (en) 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
EP4017476A1 (en) 2019-08-19 2022-06-29 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
CA3155068A1 (en) 2019-09-29 2021-04-01 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Drug combination containing tlr7 agonist
US11497808B2 (en) 2019-09-30 2022-11-15 Gilead Sciences, Inc. HBV vaccines and methods treating HBV
WO2021067644A1 (en) 2019-10-01 2021-04-08 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
PH12022550835A1 (en) 2019-10-18 2023-07-03 Forty Seven Inc Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
CN114599392A (zh) 2019-10-31 2022-06-07 四十七公司 基于抗cd47和抗cd20的血癌治疗
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
US11807625B2 (en) 2019-11-26 2023-11-07 Gilead Sciences, Inc. Capsid inhibitors for the prevention of HIV
EP4567109A3 (en) 2019-12-06 2025-09-17 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
JP2023507322A (ja) 2019-12-20 2023-02-22 ナミ セラピューティクス， インコーポレイテッド がんの処置において有用なＴｏｌｌ様受容体（「ＴＬＲ」）アゴニストプロドラッグを含有する製剤化および／または共製剤化リポソーム組成物ならびにその方法
MX2022007930A (es) 2019-12-24 2022-08-08 Carna Biosciences Inc Compuestos moduladores de diacilglicerol quinasa.
KR20220132591A (ko) 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
KR20220132595A (ko) 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 C3-치환된 1H-피라졸로[4,3-d]피리미딘 화합물
CN115135655B (zh) 2020-01-27 2024-07-02 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
JP7684316B2 (ja) * 2020-01-27 2025-05-27 ブリストル－マイヤーズ スクイブ カンパニー トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物
KR20220132601A (ko) 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
WO2021154662A1 (en) 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
EP4097102A1 (en) 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
WO2021154666A1 (en) 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
EP4097108A1 (en) 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
MX2022009947A (es) 2020-02-14 2022-11-07 Jounce Therapeutics Inc Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos.
EP4106819A1 (en) 2020-02-21 2022-12-28 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
BR112022015771A2 (pt) 2020-02-24 2022-10-11 Gilead Sciences Inc Compostos tetracíclicos para tratar a infecção por hiv
EP4115901A4 (en) 2020-03-02 2024-04-10 Progeneer Inc. Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
CA3171250A1 (en) 2020-03-10 2021-09-16 E. Lynne KELLEY Methods for treating neutropenia
TW202421168A (zh) 2020-03-20 2024-06-01 美商基利科學股份有限公司 4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法
KR20230006891A (ko) 2020-05-01 2023-01-11 길리애드 사이언시즈, 인코포레이티드 Cd73를 억제하는 2,4-다이옥소피리미딘 화합물
EP4153181A1 (en) 2020-05-21 2023-03-29 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
TW202502766A (zh) 2020-06-25 2025-01-16 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
KR20230047361A (ko) 2020-07-01 2023-04-07 아르스 파마슈티컬스 인크. 항-asgr1 항체 접합체 및 이의 용도
US20230277525A1 (en) 2020-08-04 2023-09-07 Progeneer Inc Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof
WO2022031011A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적으로 작용하는 아주번트 앙상블
WO2022031021A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적 제어가 가능한 아주번트를 포함하는 mrna 백신
WO2022031894A1 (en) 2020-08-07 2022-02-10 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
TW202222798A (zh) 2020-09-30 2022-06-16 美商基利科學股份有限公司 橋接三環胺甲醯基吡啶酮化合物及其用途
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2022103758A1 (en) 2020-11-11 2022-05-19 Gilead Sciences, Inc. METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
KR102514860B1 (ko) * 2020-12-01 2023-03-29 한국과학기술연구원 5-ht7 세로토닌 수용체 활성 저해용 바이페닐 피롤리딘 및 바이페닐 다이하이드로이미다졸 유도체 및 이를 유효성분으로 포함하는 약학 조성물
CA3202957A1 (en) 2021-01-19 2022-07-28 Hang CHU Substituted pyridotriazine compounds and uses thereof
AU2022253902A1 (en) 2021-04-10 2023-11-02 Genmab A/S Folr1 binding agents, conjugates thereof and methods of using the same
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
TW202308699A (zh) 2021-04-23 2023-03-01 美商普方生物製藥美國公司 Ｃｄ７０結合劑、其結合物及其使用方法
EP4337223A1 (en) 2021-05-13 2024-03-20 Gilead Sciences, Inc. Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11976072B2 (en) 2021-06-23 2024-05-07 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
CN113684152A (zh) * 2021-08-30 2021-11-23 贵州安康医学检验中心有限公司 一种细菌保藏培养基及其制备方法
JP2024539252A (ja) 2021-10-28 2024-10-28 ギリアード サイエンシーズ， インコーポレイテッド ピリジジン－３（２ｈ）－オン誘導体
JP7787991B2 (ja) 2021-10-29 2025-12-17 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３化合物
CN118369316A (zh) 2021-12-03 2024-07-19 吉利德科学公司 Hiv病毒感染的治疗性化合物
JP7765637B2 (ja) 2021-12-03 2025-11-06 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖウイルス感染症のための治療化合物
CA3235937A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
WO2023107956A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
WO2023107954A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
CN118488946A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
EP4452415A1 (en) 2021-12-22 2024-10-30 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
HUE069263T2 (hu) 2022-03-17 2025-02-28 Gilead Sciences Inc Ikarosz cink-ujj család degradálói és azok alkalmazása
JP2025509662A (ja) 2022-03-24 2025-04-11 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
TWI843506B (zh) 2022-04-06 2024-05-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20230374036A1 (en) 2022-04-21 2023-11-23 Gilead Sciences, Inc. Kras g12d modulating compounds
TW202434566A (zh) 2022-07-01 2024-09-01 美商基利科學股份有限公司 可用於hiv病毒感染之疾病預防性或治療性治療的治療性化合物
PE20250758A1 (es) 2022-07-01 2025-03-13 Gilead Sciences Inc Compuestos de cd73
EP4554628A1 (en) 2022-07-12 2025-05-21 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
AU2023330037A1 (en) 2022-08-26 2025-03-06 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
EP4598934A1 (en) 2022-10-04 2025-08-13 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
KR20250122479A (ko) 2022-12-22 2025-08-13 길리애드 사이언시즈, 인코포레이티드 Prmt5 억제제 및 이의 용도
US20240383922A1 (en) 2023-04-11 2024-11-21 Gilead Sciences, Inc. KRAS Modulating Compounds
AR132464A1 (es) 2023-04-19 2025-07-02 Gilead Sciences Inc Régimen de dosificación de inhibidor de la cápside
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024249517A1 (en) 2023-05-31 2024-12-05 Gilead Sciences, Inc. Anti-hiv compounds
WO2024249592A1 (en) 2023-05-31 2024-12-05 Gilead Sciences, Inc. Quinazolinyl-indazole derivatives as therapeutic compounds for hiv
TW202504592A (zh) 2023-05-31 2025-02-01 美商基利科學股份有限公司 固體形式
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
CN119367281A (zh) * 2023-07-27 2025-01-28 苏州申拓医药科技有限公司 一种tlr7/8激动剂注射剂、其制备方法及其用途
WO2025029247A1 (en) 2023-07-28 2025-02-06 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
WO2025042394A1 (en) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
AR133955A1 (es) 2023-09-26 2025-11-19 Profoundbio Us Co Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
WO2025076542A1 (en) 2023-10-05 2025-04-10 Jones R Brad Atovaquone as an ros inducer for use in the elimination of hiv-infected t-cells
WO2025080850A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250122219A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202515549A (zh) 2023-10-11 2025-04-16 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025137245A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US20250296992A1 (en) 2024-01-10 2025-09-25 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
WO2025181219A1 (en) 2024-02-29 2025-09-04 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
US20250333424A1 (en) 2024-03-01 2025-10-30 Gilead Sciences, Inc. Antiviral compounds
WO2025184447A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
US20250289822A1 (en) 2024-03-01 2025-09-18 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US20250326779A1 (en) 2024-04-03 2025-10-23 Gilead Sciences, Inc. Anti-hiv compounds
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
US20250345389A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025260028A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors

Family Cites Families (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3798209A (en) 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
JPS5246234B2 (es) * 1972-05-02 1977-11-22
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
DE2341925A1 (de) * 1973-08-20 1975-03-06 Thomae Gmbh Dr K Neue pyrimidinderivate und verfahren zu ihrer herstellung
CH595061A5 (es) * 1974-05-10 1978-01-31 Ciba Geigy Ag
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
DE2758025A1 (de) 1977-12-24 1979-07-12 Bayer Ag Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung
JPS55111420A (en) * 1979-02-20 1980-08-28 Ono Pharmaceut Co Ltd Antitumorigenic agent
MA18829A1 (fr) * 1979-05-18 1980-12-31 Ciba Geigy Ag Derives de la pyrimidine,procedes pour leur preparation,compositions pharmaceutiques contenant ces composes et leur utilisation therapeutique
US4414220A (en) * 1980-02-20 1983-11-08 Pfizer Inc. Organic diamine therapeutic compositions
US4539205A (en) 1982-11-09 1985-09-03 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US4643992A (en) 1982-11-09 1987-02-17 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
NL8400798A (nl) 1984-03-13 1985-10-01 B M I B V Inrichting voor het bereiden van een mengsel.
US4724232A (en) 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
CS263952B1 (en) 1985-04-25 1989-05-12 Holy Antonin Remedy with antiviral effect
AU570853B2 (en) 1985-08-26 1988-03-24 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Inhibition of infectivity and cytopathic effect of htlv-111/ lav by purine bases
US6492352B1 (en) 1985-10-31 2002-12-10 Astra Lakemedel Aktiebolag Method for the control and treatment of acquired immunodeficiency syndrome (AIDS)
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4978655A (en) 1986-12-17 1990-12-18 Yale University Use of 3'-deoxythymidin-2'-ene (3'deoxy-2',3'-didehydrothymidine) in treating patients infected with retroviruses
EP0273512B1 (en) 1986-12-19 1991-02-27 Duphar International Research B.V Stabilised adjuvant suspension comprising dimethyl dioctadecyl ammonium bromide
DE3875762T2 (de) 1987-03-17 1993-05-13 Akzo Nv Adjuvanzienmischung.
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5028595A (en) 1987-09-18 1991-07-02 Hoffmann-La Roche Inc. Method for preventing AIDS in a subject or treating a subject infected with the AIDS virus
US4880784A (en) 1987-12-21 1989-11-14 Brigham Young University Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives
US5041426A (en) 1987-12-21 1991-08-20 Brigham Young University Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
CA2012681A1 (en) * 1989-03-31 1990-09-30 Masayasu Okuhira Quinolone derivatives, preparation processes thereof, and antibacterial agents containing the same
US5366972A (en) 1989-04-20 1994-11-22 Boehringer Ingelheim Pharmaceuticals, Inc. 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
US5552558A (en) 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
CA2017507C (en) * 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
JP2886570B2 (ja) 1989-09-29 1999-04-26 エーザイ株式会社 縮合ヘテロ環を有する化合物
GB8927913D0 (en) 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
US5563142A (en) 1989-12-28 1996-10-08 The Upjohn Company Diaromatic substituted compounds as anti-HIV-1 agents
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
JPH05320143A (ja) 1992-03-18 1993-12-03 Mochida Pharmaceut Co Ltd 新規ピリミジン誘導体
CZ239694A3 (en) 1992-04-01 1995-07-12 Merck & Co Inc Recombinant human antibody against hiv, cassette for expression, host cell and a pharmaceutical preparation against hiv
US5665720A (en) 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
TW274550B (es) * 1992-09-26 1996-04-21 Hoechst Ag
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
EP0743855A1 (en) * 1994-01-03 1996-11-27 Acea Pharmaceuticals, Inc. 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
JPH07330770A (ja) 1994-06-03 1995-12-19 Japan Energy Corp プリン誘導体及びそれを有効成分とする治療剤
US5646180A (en) 1995-12-05 1997-07-08 Vertex Pharmaceuticals Incorporated Treatment of the CNS effects of HIV
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
ZA973884B (en) 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
ES2232871T3 (es) 1996-07-03 2005-06-01 Sumitomo Pharmaceuticals Company, Limited Nuevos derivados de purina.
ATE232863T1 (de) 1996-08-06 2003-03-15 Pfizer Substituierte pyrido- oder pyrimidogruppen enthaltende 6,6- oder 6,7-bicyclische derivate
JPH1045736A (ja) * 1996-08-08 1998-02-17 Mitsubishi Gas Chem Co Inc メタキシリレンジアミン誘導体
US5693641A (en) * 1996-08-16 1997-12-02 Berlex Laboratories Inc. Bicyclic pyrimidine derivatives and their use as anti-coagulants
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
ES2205573T3 (es) 1997-11-28 2004-05-01 Sumitomo Pharmaceuticals Company, Limited Nuevo compuestos heterociclicos.
DK1040108T3 (da) 1997-12-19 2004-05-24 Schering Ag Orthoanthranilamidderivater som antikoagulanter
JPH11180981A (ja) * 1997-12-19 1999-07-06 Sumitomo Pharmaceut Co Ltd 複素環誘導体
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
JP4160645B2 (ja) 1997-12-24 2008-10-01 大日本住友製薬株式会社 新規アデニン誘導体及びその医薬用途
CA2321153A1 (en) * 1998-02-17 1999-08-19 Timothy D. Cushing Anti-viral pyrimidine derivatives
SE9802209D0 (sv) * 1998-06-22 1998-06-22 Astra Pharma Inc Novel compounds
CA2334332A1 (en) 1998-06-26 2000-01-06 Robert Joseph Mchugh Substituted quinoxalin-2(1h)-ones useful as hiv reverse transcriptase inhibitors
US6217921B1 (en) 1998-07-24 2001-04-17 The Procter & Gamble Company Coated low-fat and fat-free snack food products and method to prepare the same
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US6629831B2 (en) 1999-04-16 2003-10-07 Coach Wei Apparatus for altering the physical properties of fluids
NZ516872A (en) 1999-09-15 2003-10-31 Warner Lambert Co Pteridinones as kinase inhibitors
WO2001032632A2 (en) * 1999-11-01 2001-05-10 Eli Lilly And Company Pharmaceutically active 4-substituted pyrimidine derivatives
US6452325B1 (en) 2000-07-24 2002-09-17 Thermoplastic Processes, Inc. Shatterproofing of fluorescent lamps
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
EP1355663A1 (en) 2001-01-26 2003-10-29 The Immune Response Corporation Method for treating an hiv-infected individual by combining immunization with structured interruption of anti-retroviral treatment
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US7157465B2 (en) 2001-04-17 2007-01-02 Dainippon Simitomo Pharma Co., Ltd. Adenine derivatives
US6806272B2 (en) * 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
JP3876254B2 (ja) 2001-09-04 2007-01-31 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規なジヒドロプテリジノン、その製造方法及びその医薬組成物としての使用
MXPA05003193A (es) 2002-09-27 2005-06-08 Sumitomo Pharma Compuesto de adenina novedoso y uso del mismo.
US6960568B2 (en) 2002-12-17 2005-11-01 Yale University Nucleosides and related processes, pharmaceutical compositions and methods
JP2004217582A (ja) * 2003-01-16 2004-08-05 Abbott Japan Co Ltd ９ｈ−プリン誘導体
HRP20050735B1 (hr) 2003-02-26 2013-08-31 Boehringer Ingelheim Pharma Gmbh & Co.Kg Dihidropteridinoni, metoda za njihovu proizvodnju i upotrebu u obliku lijekova
US20050043239A1 (en) 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
US20050054614A1 (en) 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
ES2342069T4 (es) 2003-09-05 2011-01-26 Anadys Pharmaceuticals, Inc. Ligandos de tlr7 para el tratamiento de la hepatitis c.
JP2005089334A (ja) 2003-09-12 2005-04-07 Sumitomo Pharmaceut Co Ltd ８−ヒドロキシアデニン化合物
CA2552664A1 (en) 2004-01-08 2005-07-28 Michigan State University Methods for treating and preventing hypertension and hypertension-related disorders
US7592326B2 (en) 2004-03-15 2009-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
US8012964B2 (en) 2004-03-26 2011-09-06 Dainippon Sumitomo Pharma Co., Ltd. 9-substituted 8-oxoadenine compound
CA2566436C (en) 2004-05-13 2011-05-10 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
JP2008500338A (ja) 2004-05-25 2008-01-10 イコス・コーポレイション 造血細胞の異常増殖を治療及び／又は予防する方法
AU2005249212B2 (en) * 2004-05-28 2010-05-20 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
EP1750715A1 (en) 2004-06-04 2007-02-14 Icos Corporation Methods for treating mast cell disorders
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
US20060058286A1 (en) 2004-09-16 2006-03-16 Mark Krystal Methods of treating HIV infection
CA2598409A1 (en) 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
US7498409B2 (en) 2005-03-24 2009-03-03 Schering Corporation Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists
JP2008534479A (ja) * 2005-03-25 2008-08-28 テイボテク・フアーマシユーチカルズ・リミテツド Ｈｃｖの複素二環式阻害剤
EA200702235A1 (ru) 2005-05-04 2008-04-28 Пфайзер Лимитед Производные 2-амидо-6-амино-8-оксопурина в качестве модуляторов toll-подобных рецепторов для лечения рака и вирусных инфекций, таких как гепатит с
FR2889189A1 (fr) * 2005-07-28 2007-02-02 Cerep Sa Composes derives d'hydantoine et leur utilistion en tant qu'antagonistes de mchr-1
JP2009503014A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系疾患の治療におけるジヒドロプテリジノン
EP1931352B1 (en) 2005-08-22 2016-04-13 The Regents of The University of California Tlr agonists
RS20080128A (sr) 2005-09-02 2009-05-06 Pfizer Inc., 1h-imidazopiridini supstituisani hidroksi grupom i postupci za dobijanje
TW200801003A (en) 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
EP1939198A4 (en) 2005-09-22 2012-02-15 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
JPWO2007034917A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規なアデニン化合物
TW200745114A (en) 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
US20090099216A1 (en) 2005-09-22 2009-04-16 Astrazeneca Aktiebolag A Corporation Of Sweden Novel adenine compound
WO2007034817A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
WO2007034882A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
PT1942108E (pt) * 2005-10-28 2013-10-24 Ono Pharmaceutical Co Composto com um grupo básico e a sua utilização
KR20080083270A (ko) 2005-11-04 2008-09-17 콜레이 파마시티컬 그룹, 인코포레이티드 하이드록시 및 알콕시 치환된 1에이치 이미다조퀴놀린 및방법
US20090317825A1 (en) 2005-12-12 2009-12-24 Elan Pharma International Limited Assay for parkinson's disease therapeutics and enzymatically active parkin preparations useful therein
ES2395386T3 (es) * 2005-12-21 2013-02-12 Abbott Laboratories Compuestos antivirales
NZ570530A (en) 2006-02-14 2011-09-30 Vertex Pharma Pharmaceutical compositions comprising 6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4)diazepine derivatives
JP2009528989A (ja) 2006-02-17 2009-08-13 ファイザー・リミテッド Ｔｌｒ７変調剤としての３−デアザプリン誘導体
MX2008011257A (es) 2006-03-08 2008-09-25 Amgen Inc Derivados de quinolina e isoquinolina como inhibidores de fosfodiesterasa 10.
CA2644716A1 (en) 2006-03-13 2007-09-27 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2007106852A2 (en) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Substituted fused[1,2]imidazo[4,5-c] ring compounds and methods
CA2653941C (en) 2006-05-31 2013-01-08 The Regents Of The University Of California Substituted amino purine derivatives and uses thereof
CN101479269A (zh) 2006-06-23 2009-07-08 阿斯利康(瑞典)有限公司 蝶啶衍生物及其作为组织蛋白酶抑制剂的用途
WO2008004948A1 (en) 2006-07-05 2008-01-10 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of tlr7
WO2008003149A2 (en) * 2006-07-06 2008-01-10 Gilead Sciences , Inc. Substituted pteridines for the treatment and prevention of viral infections
WO2008005555A1 (en) 2006-07-07 2008-01-10 Gilead Sciences, Inc. Modulators of toll-like receptor 7
US7866135B2 (en) 2006-08-28 2011-01-11 Exmark Manufacturing Company, Inc. Flow control baffle for turf mower
KR20140104060A (ko) 2006-10-19 2014-08-27 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도
TW200829258A (en) 2006-11-06 2008-07-16 Boehringer Ingelheim Int Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200831105A (en) 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
ATE490249T1 (de) 2007-02-19 2010-12-15 Glaxosmithkline Llc Purinderivate als immunmodulatoren
ES2779826T3 (es) 2007-02-23 2020-08-20 Gilead Sciences Inc Moduladores de propiedades farmacocinéticas de agentes terapéuticos
WO2008114006A1 (en) 2007-03-19 2008-09-25 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators
JP5480637B2 (ja) 2007-03-19 2014-04-23 アストラゼネカ・アクチエボラーグ Ｔｏｌｌ様受容体（ｔｌｒ７）モジュレーターとしての９−置換−８−オキソ−アデニン化合物
WO2008114819A1 (ja) 2007-03-20 2008-09-25 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
TW200902018A (en) 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Novel adenine compound
SI2139892T1 (sl) 2007-03-22 2011-12-30 Takede Pharmaceutical Company Ltd Substituirani pirimidodiazepini, uporabni kot PLK1 inhibitorji
WO2008124703A2 (en) 2007-04-05 2008-10-16 Siemens Medical Solutions Usa, Inc. Development of molecular imaging probes for carbonic anhydrase-ix using click chemistry
WO2008124575A1 (en) 2007-04-05 2008-10-16 Smithkline Beecham Corporation Renin inhibitors
JP5313883B2 (ja) 2007-04-18 2013-10-09 キッセイ薬品工業株式会社 含窒素縮合環誘導体、それを含有する医薬組成物及びその医薬用途
KR20100016289A (ko) 2007-05-08 2010-02-12 아스트라제네카 아베 면역-조정 특성의 이미다조퀴놀린
AU2008255016B2 (en) 2007-05-15 2013-05-09 Stryker Corporation Concentrated protein preparations of bone morphogenetic proteins and methods of use thereof
JP2009007273A (ja) 2007-06-27 2009-01-15 Ajinomoto Co Inc ジアミノピリミジン化合物の製造方法
MX2009013832A (es) 2007-06-29 2010-03-10 Gilead Sciences Inc Derivados de purina y su uso como moduladores del receptor 7 similar a un puente.
WO2009019553A2 (en) * 2007-08-03 2009-02-12 Pfizer Limited Imidazopyridinones
CN101952291A (zh) 2007-08-15 2011-01-19 弗特克斯药品有限公司 用作人蛋白激酶plk1至plk4的抑制剂以治疗增殖疾病的4-(9-(3,3-二氟环戊基)-5,7,7-三甲基-6-氧代-6,7,8,9-四氢-5h-嘧啶并[4,5-b][1,4]二氮杂䓬-2-基氨基)-3-甲氧基苯甲酰胺衍生物
WO2009022185A2 (en) * 2007-08-16 2009-02-19 Astrazeneca Ab 6, 6-fused heterocycles, their pharmaceutical compositions and methos of use
WO2009062285A1 (en) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
US20090291938A1 (en) 2007-11-19 2009-11-26 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
PE20091156A1 (es) * 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
CN102015714B (zh) 2008-04-23 2014-09-24 吉里德科学公司 用于抗病毒治疗的1’-取代的carba-核苷类似物
WO2009151910A2 (en) 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
CN101284810A (zh) 2008-06-02 2008-10-15 秦引林 氰基吡咯烷和氰基噻唑烷衍生物
WO2009155332A1 (en) 2008-06-17 2009-12-23 Cedars-Sinai Medical Center Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
CA2732437C (en) 2008-08-01 2017-11-21 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
JP5519670B2 (ja) 2008-08-11 2014-06-11 グラクソスミスクライン エルエルシー アレルギー性、炎症性及び感染性疾患治療用のプリン誘導体
KR101616396B1 (ko) 2008-08-11 2016-04-28 글락소스미스클라인 엘엘씨 신규의 아데닌 유도체
US8802684B2 (en) 2008-08-11 2014-08-12 Glaxosmithkline Llc Adenine derivatives
WO2010018132A1 (en) 2008-08-11 2010-02-18 Smithkline Beecham Corporation Compounds
EP2324025A1 (en) 2008-08-11 2011-05-25 Smithkline Beecham Corporation Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
HUE036531T2 (hu) 2008-10-24 2018-07-30 Glaxosmithkline Biologicals Sa Lipidált imidazokinolin származékok
CA2745295C (en) 2008-12-09 2017-01-10 Gilead Sciences, Inc. Modulators of toll-like receptors
WO2010093705A2 (en) 2009-02-10 2010-08-19 Idera Pharmaceuticals, Inc. Synthetic rna-based agonists of tlr7
AU2010214112B2 (en) 2009-02-11 2015-04-09 The Regents Of The University Of California Toll-like receptor modulators and treatment of diseases
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
GB0908772D0 (en) 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756
EP2467380B1 (en) 2009-08-18 2016-11-30 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
PT2477987T (pt) 2009-09-14 2018-03-13 Gilead Sciences Inc Moduladores de recetores do tipo toll
EP2480572B1 (en) 2009-09-25 2019-01-30 The United States of America, as represented by The Secretary, Department of Health and Human Services Neutralizing antibodies to hiv-1 and their use
SG10201406813RA (en) 2009-10-22 2014-11-27 Gilead Sciences Inc Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
EP2588450B1 (en) 2010-07-02 2017-05-24 Gilead Sciences, Inc. Napht-2-ylacetic acid derivatives to treat aids
SG186821A1 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
EP4549461A3 (en) 2010-08-31 2025-08-06 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv)-neutralizing antibodies
AU2011349844B2 (en) 2010-12-20 2017-06-01 Gilead Sciences, Inc. Combinations for treating HCV
SG194512A1 (en) 2011-04-21 2013-12-30 Gilead Sciences Inc Benzothiazole compounds and their pharmaceutical use
EP2701736A1 (en) 2011-04-25 2014-03-05 Advanced Bioscience Laboratories, Inc. Truncated hiv envelope proteins (env), methods and compositions related thereto
US8728486B2 (en) 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
AP2014007575A0 (en) 2011-09-16 2012-04-30 Gilead Pharmasset Llc Methods for treating HCV
US20130109647A1 (en) 2011-10-31 2013-05-02 Gilead Pharmasset Llc Methods and compositions for treating hepatitis c virus
EP2776439B1 (en) 2011-11-09 2018-07-04 Janssen Sciences Ireland UC Purine derivatives for the treatment of viral infections
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
US20150105350A1 (en) 2012-02-03 2015-04-16 Gilead Sciences, Inc. Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
AU2013229432A1 (en) 2012-03-08 2014-10-16 Novartis Ag Adjuvanted formulations of booster vaccines
CA2850881C (en) 2012-04-20 2021-02-16 Gilead Sciences, Inc. Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection
CN104603146B (zh) 2012-09-29 2018-01-02 诺华股份有限公司 环肽类化合物及其作为药物的用途
WO2014063059A1 (en) 2012-10-18 2014-04-24 Rockefeller University (The) Broadly-neutralizing anti-hiv antibodies
US9415070B2 (en) 2012-11-09 2016-08-16 Massachusetts Institute Of Technology Methods and compositions for localized delivery of agents to virally infected cells and tissues
EP3052132B1 (en) 2013-09-30 2020-07-29 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
MA40238A (fr) 2014-07-11 2017-05-17 Gilead Sciences Inc Modulateurs de récepteurs de type toll pour le traitement du vih
US9573952B2 (en) 2014-09-16 2017-02-21 Gilead Sciences, Inc. Methods of preparing toll-like receptor modulators
BR102015023450A2 (pt) 2014-09-16 2016-04-12 Gilead Sciences Inc formas sólidas de um modulador do receptor semelhante a toll
TW202408568A (zh) 2019-05-22 2024-03-01 美商基利科學股份有限公司 Tlr7調節化合物及hiv疫苗之組合

Also Published As

Publication number Publication date
KR101687841B1 (ko) 2016-12-19
PT2364314E (pt) 2014-06-09
BRPI0923305A2 (pt) 2016-12-13
ZA201104998B (en) 2012-03-28
TWI534136B (zh) 2016-05-21
SG172060A1 (en) 2011-07-28
KR20110098809A (ko) 2011-09-01
JP5945567B2 (ja) 2016-07-05
DK2364314T3 (da) 2014-05-12
US20190321366A1 (en) 2019-10-24
PE20120106A1 (es) 2012-02-20
US8367670B2 (en) 2013-02-05
TW201031667A (en) 2010-09-01
JP2012511577A (ja) 2012-05-24
TW201441204A (zh) 2014-11-01
HK1205737A1 (en) 2015-12-24
PT2818469T (pt) 2017-05-05
EA021377B9 (ru) 2015-09-30
CN103497192A (zh) 2014-01-08
EA021377B1 (ru) 2015-06-30
KR101787309B1 (ko) 2017-10-18
NZ612380A (en) 2015-01-30
WO2010077613A1 (en) 2010-07-08
CN102272134B (zh) 2013-10-16
EP2818469A1 (en) 2014-12-31
US10172860B2 (en) 2019-01-08
US20170065592A1 (en) 2017-03-09
TW201623255A (zh) 2016-07-01
EP2818469B1 (en) 2017-02-15
JP2014208692A (ja) 2014-11-06
MX2011006152A (es) 2011-07-28
AR074506A1 (es) 2011-01-19
EA026557B1 (ru) 2017-04-28
ES2623794T3 (es) 2017-07-12
EP2364314A1 (en) 2011-09-14
US20180085370A1 (en) 2018-03-29
US11110091B2 (en) 2021-09-07
US20140316132A1 (en) 2014-10-23
HRP20140539T1 (hr) 2014-07-18
JP6104432B2 (ja) 2017-03-29
EA201692167A1 (ru) 2017-07-31
AP2011005745A0 (en) 2011-06-30
BRPI0923305B1 (pt) 2019-01-22
HK1161880A1 (en) 2012-08-10
CA2745295C (en) 2017-01-10
EP3210982A1 (en) 2017-08-30
IL236272A (en) 2016-09-29
EP2364314B1 (en) 2014-03-12
CN102272134A (zh) 2011-12-07
JP5600116B2 (ja) 2014-10-01
PL2364314T3 (pl) 2014-08-29
SMT201400083B (it) 2014-09-08
TWI432436B (zh) 2014-04-01
US20140081022A1 (en) 2014-03-20
AU2009333559B2 (en) 2015-03-12
TW201529559A (zh) 2015-08-01
TWI480268B (zh) 2015-04-11
NZ593110A (en) 2013-06-28
EA201491607A1 (ru) 2015-07-30
EA201190021A1 (ru) 2012-04-30
US9127006B2 (en) 2015-09-08
US8629142B2 (en) 2014-01-14
ES2467108T3 (es) 2014-06-11
AU2009333559A1 (en) 2011-07-14
US20130071354A1 (en) 2013-03-21
RS53347B (sr) 2014-10-31
IL236272A0 (en) 2015-01-29
TWI557117B (zh) 2016-11-11
TW201639852A (zh) 2016-11-16
CL2011001392A1 (es) 2011-11-11
KR20160142898A (ko) 2016-12-13
US8809527B2 (en) 2014-08-19
IL213101A (en) 2014-12-31
ECSP11011189A (es) 2011-08-31
US20160015713A1 (en) 2016-01-21
JP2016172762A (ja) 2016-09-29
US20100143301A1 (en) 2010-06-10
UY32306A (es) 2010-07-30
CY1115176T1 (el) 2016-12-14
IL213101A0 (en) 2011-07-31
SI2364314T1 (sl) 2014-07-31
CN103497192B (zh) 2015-09-23
CA2745295A1 (en) 2010-07-08
US9452166B2 (en) 2016-09-27
CO6362010A2 (es) 2012-01-20

Similar Documents

Publication Publication Date Title
ECSP11011310A (es) Análogos carba - nucleósido para tratamiento antiviral
ECSP10010618A (es) Análogos carba - nucleósidos para tratamiento antiviral
CL2012001959A1 (es) Compuestos derivados del acido tiofeno-2-carboxilico, inhibidores de virus flaviviridae; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral por flaviviridae.
ECSP099319A (es) Analogos de tiofeno para el tratamiento o prevencion de las infecciones por flavivirus
ECSP109904A (es) Compuestos antivirales
CL2016000805A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
ECSP12011684A (es) Inhibidores de los virus flaviviridae.
UA116083C2 (uk) Похідні пурину для лікування вірусних інфекцій
ECSP15000435A (es) Inhibidores macrocíclicos de virus flaviviridae
MX2020002151A (es) Compuestos antivirales.
CL2014000612A1 (es) Compuestos derivados de prolinas macrociclicas, inhibidores de las proteasas de serina del virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; y su uso para tratar una infeccion viral tal como la infeccion por el virus de la hepatitis c (vhc).
CL2014001641A1 (es) Compuestos derivados de nucleosidos sustituidos, nucleotidos y analogos de los mismos; composicion farmaceutica; y uso para mejorar o tratar una infeccion viral.
CR20160123A (es) Inhibidores de polimerasa hcv
ECSP13013021A (es) Compuestos de benzotiazol y su uso farmacéutico
ECSP12012104A (es) Inhibidores de virus flaviviridae
CR20150085A (es) Nuevas 6-aminoacido-heteroarildihidropirmidindas para el tratamiento y profilaxis de la infección del virus de la hepatitis b
CL2012002782A1 (es) Compuestos derivados de pirazol-4-il-heterociclil-carboxamida, inhibidores de los trastornos mediados por las quinasas pim-1, pim-2 y pim-3; composición farmacéutica; mètodo de tratamiento; y su uso para el tratamiento del càncer, trastornos inmunes, enfermedades cardiovasculares e infecciones virales , entre otros.
UY33097A (es) DERIVADOS DE (1h-PIRAZOL-5-IL)UREIDOARILO 1,3-DISUSTITUIDOS Y SUS USOS TERAPÉUTICOS
CL2014002392A1 (es) Uso de nucleosidos, nucleotidos sustituidos y análogos de los mismos para el tratamiento de una infeccion viral.
UA113651C2 (xx) Макроциклічні пурини для лікування вірусних інфекцій
ECSP14013315A (es) Inhibidores de aplicación viral
CL2017002709A1 (es) Compuestos de pirazolo - y triazolo - pirimidina antivirales contra vsr
CO6660514A2 (es) Derivados de ácido 2 quinolinil acético como compuestos antivirales del vih
UY35155A (es) Derivados cíclicos de nucleósidos y usos de los mismos
UY34066A (es) Inhibidores del virus de la hepatitis c